|

Risk of Sudden Cardiac Death in UN Athletes

RECRUITINGSponsored by Universidad Nacional de Colombia
Actively Recruiting
SponsorUniversidad Nacional de Colombia
Started2023-11-24
Est. completion2024-12-20
Eligibility
Age18 Years – 35 Years
Healthy vol.Accepted

Summary

The detection of sudden cardiac death risk in athletes is a topic of great relevance in the field of sports physiotherapy and physical activity. High-performance sports practice involves anatomical and physiological changes that can modify the mechanical and electrical properties of the heart, increasing the risk of potentially fatal cardiac events. Therefore, it is essential to implement early detection strategies to identify at-risk athletes and prevent tragedies during sports practice. Methodology: This study focuses on the prevalence of sudden cardiac death risk, using a 12-lead electrocardiogram as the primary detection tool. This examination will allow for the evaluation of the heart's electrical activity and the detection of potential anomalies that could predispose athletes to adverse cardiac events during sports practice. In addition to the electrocardiogram, cardiovascular screening questionnaires will be administered to collect information on personal and family health histories, as well as other relevant risk factors. In conjunction with the project's researchers, the sports medical team of the Universidad Nacional de Colombia will be responsible for conducting the evaluations, ensuring the precision and reliability of the obtained results. A detailed analysis of the collected data will be performed using statistical tools to identify possible correlations between the evaluated risk factors and the presence of sudden cardiac death risk in athletes. Logistic regression models will be employed to determine the strength of association between the studied variables and cardiovascular risk in this specific population. Expected Results: It is anticipated that implementing pre-participation evaluations, including the electrocardiogram and cardiovascular screening questionnaires, will enable the identification of athletes at higher risk of sudden cardiac death. These results will allow for the establishment of individualized risk profiles and the design of personalized prevention strategies for each athlete. Additionally, it is expected that the findings of this study will contribute to the development of early detection protocols for sudden cardiac death risk in athletes, which can be effectively implemented in sports settings. The information generated from this study will provide a solid foundation for clinical decision-making and the implementation of preventive measures to benefit the health and well-being of high-performance athletes.

Eligibility

Age: 18 Years – 35 YearsHealthy volunteers accepted
Inclusion Criteria:

* Athletes belonging to the sports teams of the National University of Colombia, Bogotá campus.
* Subject's sports history (practice time exceeding 2 years).
* Individuals aged 18 to 35 years, without discrimination based on biological sex.
* Training time exceeding 6 hours per week in their sports modality (weekly training record).
* Personal history of cardiovascular disease (cardiac malformations or previously detected sudden death risk).
* Athletes who attend at least 90% of the training sessions planned by the coach.

Exclusion Criteria:

* Personal history of metabolic (type 1 and 2 diabetes mellitus), neurological (spinal cord injury), or renal disease.
* Routine consumption of alcohol or psychoactive substances.
* Use of antihypertensive medications, beta-blockers, or inotropes.
* Cardiovascular disease diagnosed with previously established pharmacological management.

Conditions5

Athlete HeartAthletic InjuriesDeath, Sudden, CardiacElectrocardiogram QT ProlongedHeart Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.